We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

65 hedge funds and large institutions have $30.9M invested in Akebia Therapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

475% more call options, than puts

Call options by funds: $466K | Put options by funds: $81K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 15

0% less capital invested

Capital invested by funds: $30.9M → $30.9M (-$36.1K)

0.2% less ownership

Funds ownership: 28.41% → 28.21% (-0.2%)

13% less funds holding

Funds holding: 75 → 65 (-10)

50% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 16

Holders
65
Holders Change
-10
Holders Change %
-13.33%
% of All Funds
1.04%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
15
Reduced
15
Closed
16
Calls
$466K
Puts
$81K
Net Calls
+$385K
Net Calls Change
+$24K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$972K
2
AIM
Alerce Investment Management
Illinois
+$852K
3
Morgan Stanley
Morgan Stanley
New York
+$231K
4
Victory Capital Management
Victory Capital Management
Texas
+$182K
5
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
+$140K

Top Sellers

Rank Fund Capital Flow
1
OCM
Ovata Capital Management
Hong Kong
-$767K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$623K
3
Renaissance Technologies
Renaissance Technologies
New York
-$418K
4
Jane Street
Jane Street
New York
-$365K
5
Millennium Management
Millennium Management
New York
-$330K
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
26
Virtu Financial
New York
$55K +$74.8K +97,854 New
UBS Group
27
UBS Group
Switzerland
$49.3K +$22.3K +29,220 +50%
Franklin Resources
28
Franklin Resources
California
$46.2K – – –
JP Morgan Chase
29
JP Morgan Chase
New York
$45K +$59.2K +77,503 +1,916%
Charles Schwab
30
Charles Schwab
California
$44.7K -$40.2K -52,566 -40%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$40.3K – – –
HighTower Advisors
32
HighTower Advisors
Illinois
$40K +$8.35K +10,925 +18%
Goldman Sachs
33
Goldman Sachs
New York
$38K +$40.1K +52,516 +343%
OCM
34
Orchard Capital Management
Illinois
$37.4K – – –
EDRH
35
Edmond de Rothschild Holding
Switzerland
$28K – – –
IWP
36
Icon Wealth Partners
Texas
$28K +$38.2K +50,000 New
Jane Street
37
Jane Street
New York
$25.9K -$365K -477,510 -91%
Mackenzie Financial
38
Mackenzie Financial
Ontario, Canada
$23.2K -$20.4K -26,718 -39%
CAMG
39
CWA Asset Management Group
Florida
$16.3K – – –
LPL Financial
40
LPL Financial
California
$16K +$21.8K +28,596 New
JJBC
41
James J. Burns & Company
New York
$14K – – –
TRCT
42
Tower Research Capital (TRC)
New York
$13K +$4.34K +5,685 +33%
WE
43
Wealth Effects
Massachusetts
$10.3K – – –
SS
44
Sunbelt Securities
Texas
$7.88K – – –
BRWA
45
B. Riley Wealth Advisors
Florida
$7.29K +$9.93K +13,000 New
OBWG
46
Onyx Bridge Wealth Group
New York
$7K – – –
Assenagon Asset Management
47
Assenagon Asset Management
Luxembourg
$6.98K +$9.51K +12,450 New
Wells Fargo
48
Wells Fargo
California
$6.87K -$928 -1,215 -9%
EP
49
Eudaimonia Partners
Tennessee
$6.81K +$9.28K +12,144 New
SIMG
50
Sonora Investment Management Group
Arizona
$5.6K -$829 -1,085 -10%
1
2
3 4

AKBA Hedge Fund Activity: Q1 2023 in Review

65 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2023, worth a combined $30.9M — down 0.12% from $30.9M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of AKBA and 8 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 15 added.

The largest buyer was Vanguard Group, adding an estimated $972K. The largest seller was Ovata Capital Management, exiting entirely with an estimated $767K sold.

  • 65 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2023, down from 75 in Q4 2022.
  • Funds reported $30.9M of Akebia Therapeutics stock for Q1 2023, down 0.12% quarter-over-quarter.
  • 8 funds opened new Akebia Therapeutics positions in Q1 2023 and 16 closed out, a net change of -8 holders.
  • The largest Akebia Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $972K added.
  • The largest Akebia Therapeutics seller in Q1 2023 was Ovata Capital Management, an estimated $767K sold.

Based on aggregated 13F filings for Q1 2023.